Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea

• DOI: 10.5414/cpp44014
• Publication Date: 2011-03-25T07:46:41Z
• Authors: M. Dworacka; M. Abramczyk; H. Winiarska; S. Kuczynski; M. Borowska; K. Szczawinska
• Keywords: Proinsulin; Amylin; C-peptide; Sulfonylurea

Hyperproinsulinemia in type 2 diabetic subjects has recently been accepted as an independent cardiovascular risk factor. Moreover, it confirmed that high proinsulin concentrations stimulate amylin secretion by pancreatic beta-cells and amyloid accumulation within islets leading to impairment of secretory function. The association between sulfonylureas administration function beta-cells, especially concerning insulin precursor peptides, is not sufficiently elucidated. Preliminary studies our research group revealed the fasting serum concentration significantly higher patients treated with than a well-matched only.A total 101 diabetes were either (n = 32), 40), + 17) or diet alone 12).The basal four groups comparable (C-peptide level > 0.5 ng/l). An effect glycemia, long-term metabolic control (HbA1c), postprandial hyperglycemia (1,5-anhydro-D-glucitol), resistance (HOMA(IR)score) duration on could be excluded.The disproportionately levels are due therapy. control, hyperglycemia, peripheral resistance.